Olodaterol	NN
shows	VBZ
anti-fibrotic	JJ
efficacy	NN
in	IN
in	FW
vitro	FW
and	CC
in	FW
vivo	FW
models	NNS
of	IN
pulmonary	JJ
fibrosis	NN
.	.

BACKGROUND	NN
AND	CC
PURPOSE	NN
:	:
Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
fatal	JJ
respiratory	JJ
disease	NN
characterized	VBN
by	IN
excessive	JJ
fibroblast	NN
activation	NN
ultimately	RB
leading	VBG
to	TO
scarring	NN
of	IN
the	DT
lungs	NNS
.	.

Although	IN
,	,
the	DT
activation	NN
of	IN
b2	NN
--	:
adrenoceptors	NNS
(	(
b2	NN
--	:
AR	NN
)	)
has	VBZ
been	VBN
shown	VBN
to	TO
inhibit	VB
pro-fibrotic	JJ
events	NNS
primarily	RB
in	IN
cell	NN
lines	NNS
,	,
the	DT
role	NN
of	IN
b2	NN
-	:
adrenoceptor	NN
agonists	NNS
has	VBZ
not	RB
yet	RB
been	VBN
fully	RB
characterized	VBN
.	.

The	DT
aim	NN
of	IN
our	PRP$
study	NN
was	VBD
to	TO
explore	VB
the	DT
anti-fibrotic	JJ
activity	NN
of	IN
the	DT
long-acting	JJ
b2	NN
-	:
adrenoceptor	NN
agonist	NN
olodaterol	NN
in	IN
primary	JJ
human	JJ
lung	NN
fibroblasts	NNS
(	(
HLF	NN
)	)
and	CC
in	IN
murine	JJ
models	NNS
of	IN
pulmonary	JJ
fibrosis	NN
.	.

EXPERIMENTAL	JJ
APPROACH	NN
:	:
We	PRP
assessed	VBD
the	DT
activity	NN
of	IN
olodaterol	NN
to	TO
inhibit	VB
various	JJ
pro-fibrotic	JJ
mechanisms	NNS
,	,
induced	VBN
by	IN
different	JJ
pro-fibrotic	JJ
mediators	NNS
,	,
in	IN
primary	JJ
HLF	NN
from	IN
control	NN
donors	NNS
and	CC
patients	NNS
with	IN
IPF	NN
(	(
IPF-LF	NN
)	)
.	.

The	DT
in	FW
vivo	FW
anti-fibrotic	JJ
activity	NN
of	IN
olodaterol	NN
,	,
given	VBN
once	RB
daily	RB
by	IN
inhalation	NN
in	IN
either	CC
a	DT
preventive	JJ
or	CC
therapeutic	JJ
treatment	NN
regimen	NN
,	,
was	VBD
explored	VBN
in	IN
murine	JJ
models	NNS
of	IN
lung	NN
fibrosis	NN
induced	VBN
by	IN
either	CC
bleomycin	NN
or	CC
the	DT
overexpression	NN
of	IN
TGF-b1	NN
.	.

KEY	JJ
RESULTS	NNS
:	:
In	IN
both	DT
HLF	NN
and	CC
IPF-LF	NN
,	,
olodaterol	NN
attenuated	VBD
TGF-b-induced	JJ
expression	NN
of	IN
a-smooth-muscle-actin	NN
,	,
fibronectin	NN
and	CC
endothelin-1	NN
(	(
ET-1	NN
)	)
,	,
FGF	NN
-	:
and	CC
PDGF-induced	JJ
motility	NN
and	CC
proliferation	NN
and	CC
TGF-b/ET	NN
-1-induced	JJ
contraction	NN
.	.

In	FW
vivo	FW
olodaterol	NN
significantly	RB
attenuated	VBD
the	DT
bleomycin-induced	JJ
increase	NN
in	IN
lung	NN
weight	NN
,	,
reduced	VBD
bronchoalveolar	JJ
lavage	NN
cell	NN
counts	NNS
and	CC
inhibited	VBD
release	NN
of	IN
pro-fibrotic	JJ
mediators	NNS
(	(
TGF	NN
-	:
,	,
MMP-9	NN
and	CC
tissue	NN
inhibitor	NN
of	IN
metalloproteinase-1	NN
)	)
.	.

Forced	VBN
vital	JJ
capacity	NN
was	VBD
increased	VBN
only	RB
with	IN
the	DT
preventive	JJ
treatment	NN
regimen	NN
.	.

In	IN
the	DT
TGF-b-overexpressing	JJ
model	NN
,	,
olodaterol	NN
additionally	RB
reduced	VBD
the	DT
Col3A1	NN
mRNA	NN
expression	NN
.	.

CONCLUSION	NN
AND	CC
IMPLICATIONS	NNS
:	:
Olodaterol	NN
showed	VBD
anti-fibrotic	JJ
properties	NNS
in	IN
primary	JJ
HLF	NN
from	IN
control	NN
and	CC
IPF	NN
patients	NNS
and	CC
in	IN
murine	JJ
models	NNS
of	IN
lung	NN
fibrosis	NN
.	.

